Novo Nordisk Limited. "Wegovy 0.25 mg, FlexTouch Solution for Injection in Pre-Filled Pen — Summary of Product Characteristics." electronic Medicines Compendium, April 2026, https://www.medicines.org.uk/emc/product/13799/smpc.
Wegovy 0.25mg Pen: Starting Dose
Wegovy 0.25mg is the starting dose of semaglutide. Taken once weekly as an easy-to-use pen injection, it curbs appetite and stabilises blood sugar to support weight loss.
Achieve more with Voy
Voy patients lose 53% more weight than with medication alone, backed by clinician-led care and on-demand side-effect support.

Why Voy
Your BMI

00.0
Enter your details to calculate your BMI
What to expect in your first delivery
Delivered within 1 working day in discreet packaging.
Your first delivery includes your medication and everything you need to begin your treatment safely at home.
Wegovy 0.25mg is the typical starting dose if you're new to Wegovy treatment. It's not where most weight loss happens. Its role is to help your body adjust to semaglutide gradually so you can move up to the doses that drive bigger results.
If you're switching from another provider or from Mounjaro, you may not need to start at 0.25mg. Your clinician will review your treatment history and confirm the right dose for you.

















How to order Wegovy 0.25mg
1. Complete your online assessment
Answer a few questions about your weight, goals and medical history. We'll recommend the treatment that fits.
2. Choose your plan
Select your plan length and dose. Your clinician will confirm 0.25mg as your starting dose if you're new to Wegovy. If you're switching from another provider or from Mounjaro, you may be able to start at a higher dose.
3. Delivered within 1 working day
Once approved, your Wegovy pen, needles, sharps bin, and rescue pack arrive in discreet packaging.
4. Ongoing clinical support
Track your progress, manage your dose, and connect with your clinical team through the Voy app. Call our hotline or use live chat whenever you need support.
Everyone's different, and so is every Voy treatment.
Wegovy 0.25mg FAQ
Dr Earim Chaudry (MBBS), Chief Medical Officer
Medically reviewed on 6th May, 2026.
Our medical leadership
.webp&w=3840&q=75)
Dr. Earim Chaudry is a highly accomplished digital health doctor with extensive experience in the field of online and telemedicine-based healthcare. Over the years, he has played a pivotal role in shaping the landscape of digital healthcare in the UK.
Chief Medical Officer

Helen is passionate about building and scaling clinical services that embed innovation, quality care and clinical safety at their core. With a career spanning the NHS, femtech and digital health, she has consistently kept the bigger picture in view - thinking not just about individual patients, but about the populations they belong to.
Head of Clinical Services

Katy Jackson is an experienced healthcare leader with over 25 years of experience across the NHS and private healthcare sector. Katy has held senior leadership roles including Chief Operating Officer, Chief Pharmacist, and most recently Chief Clinical Officer for the UK’s largest menopause service.
Clinical Director - Women's Health
In partnership with leading educational and research institutions
Blog
Novo Nordisk. "Wegovy Chronic Weight Management Efficacy and Safety." NovoMedLink, https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html. Accessed 6 May 2026.
Wharton, Sean, et al. "1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial." Diabetes, vol. 74, no. Supplement_1, 20 June 2025, p. 1966-LB. American Diabetes Association, https://doi.org/10.2337/db25-1966-LB.
Take the first step towards weight loss that lasts.



















